Electrostatic complementarity between proteins and ligands. 2. Ligand moieties.
Drug design strategies consider factors governing intermolecular interactions to build up putative ligands. In many strategies, the ligand is constructed using fragments which are placed in the site sequentially. The optimization is then performed with each fragment. We would like to examine if this optimization strategy could generate ligands with optimal electrostatic interactions. The electrostatic complementarities between constituent moieties and the receptor site have been calculated. The whole-ligand complementarity does not appear to be the mathematical mean of the individual complementarities, nor have we found a simple relationship between the moiety and whole-ligand complementarities. The results demonstrate clearly that, using a simple model, it is very difficult to predict the electrostatic potential complementarity of the whole ligand from the complementarities of its constituent chemical moieties. This means that ligand design strategies must optimize the electrostatic complementarity globally, and not moiety by moiety.
Chau
P L
PL
Department of Pharmacology, University of Cambridge, U.K.
Dean
P M
PM
D015109:4-Hydroxybenzoate-3-Monooxygenase / Q000737:chemistry; D000595:Amino Acid Sequence; D001665:Binding Sites; D017076:Computer-Aided Design; D015195:Drug Design; D004563:Electrochemistry; D005182:Flavin-Adenine Dinucleotide / Q000737:chemistry; D008024:Ligands; D008969:Molecular Sequence Data; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry; D011506:Proteins / Q000737:chemistry*
D008024:Ligands; D009842:Oligopeptides; D011506:Proteins; D005182:Flavin-Adenine Dinucleotide; D015109:4-Hydroxybenzoate-3-Monooxygenase